To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 5 December 2023 to Question 4318 on Prostate Cancer: Drugs, if he will make a comparative assessment of the (a) decision-making criteria for and (b) process to approve the use of abiraterone acetate to treat locally advanced high-risk non-metastatic prostate cancer in (i) NHS England and NHS Wales and (ii) NHS Scotland.
Answered on
12 December 2023
There are no plans for a comparative assessment to be made. Health is a devolved matter and decisions on access to medicines in Scotland and Wales are a matter for the devolved administrations.
NHS England sent a policy proposition to stakeholders on 29 November 2023 regarding abiraterone acetate and prednisolone for high-risk, hormone sensitive, non-metastatic prostate cancer, and has invited feedback by 14 December 2023. The completion of NHS England’s consideration will depend on the feedback received from stakeholders which will help inform the final draft of the proposition, and the outcome of the impact assessment which will inform the timing of decision making.